Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Status:
Terminated
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The general objective of this study is to improve the Quality of Life (QoL) of selected
patients with advanced carcinoma of the lung. The specific objective is to evaluate the
effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related
QoL and anemia in non-small cell lung cancer patients with advanced stage disease and
underlying anemia of malignancy.